PharmaGraphX

Log in Get Started

Olaparib

Lynparza

Uncategorized

Standard

Half-life

11.9 hours

Protein Binding

82%

Metabolized By

N/A

External

Drugs.com

Mechanism of action

Inhibits poly(ADP-ribose) polymerase; synthetic lethality in BRCA-mutant cells

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Advanced Bladder Carcinoma
·Advanced Genitourinary System Carcinoma
·Metastatic Bladder Carcinoma
·Metastatic Genitourinary System Carcinoma
·Stage III Bladder Cancer AJCC v8

Interactions

No curated interaction pairs are recorded for Olaparib. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nausea
Fatigue
Anemia
Vomiting
Diarrhea

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Pharmacokinetics

Half-life: 11.9 hours
Protein binding: 82%
Metabolised by: CYP3A4

Pregnancy & lactation

Not recorded for Olaparib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement